摘要
目的:探讨希罗达同期放、化疗对中晚期鼻咽癌患者治疗的安全性和有效性。方法:将2006年1月～2007年10月就诊我院的50例初诊局部晚期(Ⅲ、Ⅳ期)鼻咽癌病人随机分为IMRT组和IMRT+希罗达组。化疗方法为希罗达750～1 000 mg/m2,每天2次口服(第1～14天),3周为1个疗程,共2个疗程。放射治疗于第1程化疗的第1天开始,给予调强根治性放疗。结果:IMRT+希罗达组完全缓解(CR)23例,CR率为92%,IM-RT CR20例,CR率80%。IMRT+希罗达组病人8例(32%)IMRT组4例(16%)出现Ⅲ度口腔粘膜炎,IMRT+希罗达组病人5例(20%)IMRT组2例(8%)出现Ⅲ度放射性皮炎,无治疗相关死亡。结论:初步结果显示希罗达同步放疗,治疗中晚期鼻咽癌病人是一个安全、方便、耐受良好且疗效高的治疗方法,值得临床推广应用。
Objective： To investigate the efficacy and tolerability of concurrent chemoradiotherapy in the treatment of the patients with advanced nasopharyngeal carcinoma. Methods： Between Jan. 2006 and Oct. 2007, 50 Patients with locally advanced nasopharyngeal carcinoma were randomized to receive intensity modulated radiation therapy（IMRT） plus capecitabine or IMRT alone. Chemotherapy consisted of 2 cycles oral capecitabine （750-1 000 mg/m^2 twice daily for 2 weeks）. The cycle was repeated every 3 weeks. Radiation with standard dose was given concurrently with the first cycle of chemotherapy. Results： All were assessable for efficacy and toxicity. 23 patients （92%） had got CR in IMRT plus capecitabine group. 20 patients （80%） had got CR in IMRT goup. Grade 3 mucocitis were found in 8 patients （32%） in IMRT plus capecitabine goup and 4 patients （16%） in IMRT goup. Grade 3 dermatitis occurred in 5 patients （20%） in IMRT plus capecitabine group and 2 patients （8%） in IMRT group. There were no treatment related death. Conclusions： These preliminary results suggest that chemo-radiatherapy with capecitabine is a safe, well tolerated and effective treatment modality for advanced NPC. It can be safely used.
出处
《新疆医科大学学报》
CAS
2008年第11期1500-1503,共4页
Journal of Xinjiang Medical University
基金
卫生厅青年基金资助(2003y06)
关键词
希罗达
鼻咽癌
放射治疗
xeloda
nasopharyngealcarcinoma
radiotherapy
